Melanoma: The Radiotherapeutic point of view; review of the current literature

Reviews on Recent Clinical Trials

Volumn 6, Issue 2, 2011, Pages 127-133

  Zygogianni, A ^a   Kyrgias, G ^b   Kouvaris, J ^a   Mystakidou, K ^a   Gogas, H ^a   Kouloulias, V ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF THESSALY   (Greece)

Author keywords

Hyperthermia; Melanoma; Radiotherapy; Review

Indexed keywords

INTERFERON; INTERLEUKIN 2; TEMOZOLOMIDE;

BONE METASTASIS; BRAIN METASTASIS; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; DRUG MEGADOSE; HUMAN; HYPERTHERMIC THERAPY; LYMPH NODE METASTASIS; MALIGNANT LENTIGO; MELANOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

EID: 79953871170     PISSN: 15748871     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488711795177877     Document Type: Review

References (64)

1. Johnson TM, Dolan OM, Hamilton TA, Lu MC, Swanson NA, Lowe L. Clinical and histologic trends of melanoma. J Am Acad Dermatol 1998; 38: 681-6.
2. Gandini S, Sera F, Cattaruzza MS, et al. Meta analysis of risk factors for cutaneous melanoma: III Family history, actinic damage and fenotypic factors. Eur J Cancer 2005; 41: 2040-59.
3. Marsden J. R, Newton-Bishop J. A, Burrows L, et al. Revised U. K Guidelines for the management of Cutaneous Melanoma 2010. Br Dermatol 2010; 163(2): 238-56.
4. Attis MG, Vollmer RT. Mitotic rate in melanoma: a reexamination. Am J Clin Pathol 2007; 127: 380-4.
5. Gimotty PA, Elder DE, Fraker DL et al. Identification of high risk patients among those diagnosed with thin cutaneous melanoma. J Clin Oncol 2007; 25:1129-34.
6. Eggermont AM, Gore M. Randomized adjuvant therapy trials in melanoma: surgical and systemic. Semin Oncol 2007; 34: 509-15.
7. Lens MB, Dawes M. Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials. J Clin Oncol 2002; 20: 1818-25.
8. Khayat D, Rixe O, Martin G, et al. Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1 mm thick). Cancer 2003; 97: 1941-6.
9. Cohn-Cedermark G, Rutqvist LE, Anderson R, et al. Long term results of a randomized study by the Swedish Melanoma Study Group on 2 cm versus 5 cm resections margins for patients with cutaneus melanoma with a tumor thickness of 0.8-2.0 mm. Cancer 2000; 89: 1495-501.
10. Veronesi U, Cascinelli N, Adamus J, et al. Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1or 3 cm. N Engl J Med 1988; 318: 1159-62.
11. Balch CM, Urist MM, Karakousis CP, et al. Efficacy of 2 cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-istitutional randomized surgical trial. Ann Surg 1993; 218: 262-7.
12. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19: 3635-48.
13. Thomas JM, Newton-Bishop J, A'Hern R, et al. Excision margins in high-risk malignant melanoma. N Engl J Med 2004; 350: 757-66.
14. Ringborg U, Brahme EM, Drewiecki K. Randomized trial of a resection margin of 2 cm versus 4 cm for cutaneous malignant melanoma with a tumor thickness of more than 2 mm. World Congress on Melanoma, September 6-10, 2005; Vancouver, British Columbia.
15. Van Akkooi AC, de Wilt JH, Verhoef C, et al. High positive sentinel node identification rate by EORTC melanoma group protocol. Prognostic indicators of metastatic patterns after sentinel node biopsy in melanoma. Eur J Cancer 2006; 42: 372-80.
16. Cochran AJ, Balda BR, Starz H, et al. The Augsburg Consensus. Techniques of lymphatic mapping, sentinel lymphadenectomy, and completion lymphadenectomy in cutaneous malignancies. Cancer 2000; 89: 236-41.
17. Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2006; 355: 1307-17.
18. Crosby T, Fish R, Coles B, Mason M. Systemic treatments for metastatic cutaneous melanoma. Cochrane Database Systemat Rev 2000; Issue 2. Art. No.:CD001215.
19. Agarwala SS, Neuberg D, Park Y, Kirkwood JM. Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage IIII melanoma (E1673): a trial of the Eastern Oncology Group. Cancer 2004; 100 (8): 1692-8.
20. Hancock BW, Wheatley K, Harris S, et al. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study-United Kingdom Coordinating Committee on Cancer research randomized study of adjuvant low dose extended duration interferon Alfa 2a in high risk resected malignant melanoma. J Clin Oncol 2004; 22 (1): 53-61.
21. Gogas H, Ioannovich J, Dafni U, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferone. N Engl J Med 2006; 354(7): 709-18.
22. Gogas H, Polyzos A, Stavrinidis I, et al. Temozolamide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology group. Ann Oncol 2006; 17(12): 1835-41.
23. Slingluff CL Jr, Petroni GR, Yamshchikov GV, et al. Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low dose interleukine 2 administered either concurrently or on a delayed schedule. J Clin Oncol 2004; 22: 4474-85.
24. Patel P, Sucin S, Mortier L, et al. Extended schedule escalated dose temozolomide versus dacarbazine in stage IV malignant melanoma; final results of the randomosed phase 3 study(EORTC18032). Ann Oncol 2009; 19 (suppl.8): viii3.
25. Doss LL, Memula N. The radioresponsiveness of melanoma. Int J Radiat Oncol Biol Phys 1982; 8: 1131-4.
26. Farshad A, Burg G, Panizzon R, Dummer R. A retrospective study of 150 patients with lentigo maligna and lentigo maligna melanoma and the efficacy of radiotherapy using Grenz or soft X-rays. Br J Dermatol 2002; 146: 1042-6.
27. Hazan C, Dusza SW, Delgado R, et al. Staged excision for lentigo maligna and lentigo maligna melanoma: a retrospective analysis of 117 cases. J Am Acad Dermatol 2008; 58: 142-8.
28. Wendtner S, Brunner B, Konz B, et al. Fractionated radiotherapy of lentigo maligna melanoma in 64 patients. J Am Acad Dermatol 2000; 43: 477-82.
29. Vongtama R, Safa A, Gallardo D, Calcaterra T, Juillard G. Efficacy of radiation therapy in the local control of desmoplastic malignant melanoma. Head Neck 2003; 25: 423-8.
30. Arora A, Lowe L, Su L, et al. Wide excision without radiation for desmoplastic melanoma. Cancer 2005; 104: 1462-7.
31. Stevens G, McKay MJ. Dispelling the myths surrounding radiotherapy for treatment of cutaneous melanoma. Lancet Oncol 2006; 7: 575-83.
32. Burmeister BH, Smithers BM, Poulsen M, et al. Radiation therapy for nodal disease in malignant melanoma. World J Surg 1995; 19: 369-71.
33. Ballo MT, Strom EA, Zagars GK, et al. Adjuvant irradiation for axillary metastases from malignant melanoma. Int J Radiat Oncol Biol Phys 2002; 52: 964-72.
34. Ang KK, Peters LJ, Weber RS, et al. Postoperative radiotherapy for cutaneus melanoma of the head and neck region. Int J Radiat Oncol Biol Phys 1994; 30: 795-8.
35. Fuhrmann D, Lippold A, Borrosch F, Ellwanger U, Garbe C, Suter L. Should adjuvant radiotherapy be recommended following resection of regional lymph node metastases of malignant melanomas? Br J Dermatol 2001; 144: 66-70.
36. Burmeister BH, Smithers BM, Davis S, et al. Radiation therapy following nodal surgery for melanoma: an analysis of late toxicity. ANZ J Surg 2002; 72: 344-8.
37. Creagan ET, Cupps RE, Ivins JC, et al. Adjuvant radiation therapy for regional nodal metastases from malignant melanoma. Cancer 1978; 42: 2206-10.
38. Bonnen MD, Ballo MT, Myers JN, et al. Elective radiotherapy provides regional control for patients with cutaneous melanoma of the head and neck. Cancer 2004; 100: 383-9.
39. Ballo MT, Garden AS, Myers JN, et al. Melanoma metastatic to cervical lymph nodes: can radiotherapy replace formal dissection after local excision of nodal disease? Head Neck 2005; 27: 718-21.
40. Stevens G, Thompson JF, Firth I, O'Brien CJ, McCarthy WH, Quinn MJ. Locally advanced melanoma: results of postoperative hypofractionated radiation therapy. Cancer 2000; 88: 88-94.
41. O'Brien CJ, Petersen-Schaefer K, Stevens GN, et al. Adjuvant radiotherapy following neck dissection and parotidectomy for metastatic malignant melanoma. Head Neck 1997; 19: 589-94.
42. Burmeister BH, Mark Smithers B, Burmeister E, et al. A prospective phase II study of adjuvant postoperative radiation therapy following nodal surgery in malignant melanoma-Trans Tasman Radiation Oncology Group (TROG) Study 96.06. Radiother Oncol 2006; 81:136-42.
43. Chang DT, Amdur RJ, Morris CG, Mendenhall WM. Adjuvant radiotherapy for cutaneous melanoma: comparing hypofractionation to conventional fractionation. Int J Radiat Oncol Biol Phys 2006; 66: 1051-5.
44. Fenig E, Eidelevich E, Njuguna E, et al. Role of radiation therapy in the management of cutaneous malignant melanoma. Am J Clin Oncol 1999; 22: 184-6.
45. Seegenschmiedt MH, Keilholz L, Altendorf-Hofmann A, et al. Palliative radiotherapy for recurrent and metastatic malignant melanoma: prognostic factors for tumor response and long-term outcome: a 20-year experience. Int J Radiat Oncol Biol Phys 1999; 44: 607-18.
46. Patchell RA. The management of brain metastases. Cancer Treat Rev 2003; 29: 533-40.
47. Tarhini AA, Agarwala SS. Management of brain metastases in patients with melanoma. Curr Opin Oncol 2004; 16: 161-6.
48. Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990; 322: 494-500.
49. Vecht CJ, Haaxma-Reiche H, Noordijk EM, et al. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann Neurol 1993; 33: 583-90.
50. McWilliams RR, Brown PD, Buckner JC, et al. Treatment of brain metastases from melanoma. Mayo Clin Proc 2003; 78: 1529-36.
51. Grob JJ, Regis J, Laurans R, et al. Radiosurgery without whole brain radiotherapy in melanoma brain metastases. Club de Cancerologie Cutanee. Eur J Cancer 1998; 34: 1187-92.
52. Brown PD, Brown CA, Pollock BE, et al. Stereotactic radiosurgery for patients with 'radioresistant' brain metastases. Neurosurgery 2002; 51: 656-65.
53. Kirova YM, Chen J, Rabarijaona LI, Piedbois Y, Le Bourgeois JP. RT as palliative treatment for metastatic melanoma. Melanoma Res 1999; 9: 611-13.
54. Rate WR, Solin LJ, Turrisi AT. Palliative RT for metastatic malignant melanoma: brain metastases, bone metastases, and spinal cord compression. Int J Radiat Oncol Biol Phys 1988; 15: 859-64.
55. Konefal JB, Emami B, Pilepich MV. Analysis of dose fractionation in the palliation of metastases from malignant melanoma. Cancer 1988; 61: 243-6.
56. Katz HR. The results of different fractionation schemes in the palliative irradiation of metastatic melanoma. Int J Radiat Oncol Biol Phys 1981; 7: 907-11.
57. Sause WT, Cooper JS, Rush S, et al. Fraction size in external beam radiation therapy in the treatment of melanoma. Int J Radiat Oncol Biol Phys 1991; 20: 429-32.
58. Overgaard J, von der MH, Overgaard M. A randomized study comparing 2 high-dose per fraction radiation schedules in recurrent or metastatic malignant melanoma. Int J Radiat Oncol Biol Phys 1985; 11: 1837-9.
59. Smithers F.A. E, Moaveni Z, De Groot C, et al. The role of radiotherapy in the palliation of cutaneous melanoma metastases: a case series of 3 patients. J Plastic Reconstruct Aesthetic Surg 2010; 63(5): 727-886.
60. Emami B, Perez CA, Konefai J, Pilepich, et al. Thermoradiotherapy of malignant melanoma. Int L Hyperthermia 1988; 4: 373-81.
61. Engin K, Tupchong L, Waterman FM, Moylan DJ, Nerlinger RE, Leeper DB. Hyperthermia and radiation in advanced malignant melanoma. Int J Radiat Oncol Biol Phys 1993; 25: 87-94.
62. Overgard J, Gonzales GD, Hulshof MC, et al. Hyperthermia as an adjuvant to radiation therapy of recurrent or metastatic malignant melanoma. A multicentre randomized trial by the European Society for Hyperthermic Oncology. Int J Hyperthermia 1996; 12: 3-20.
63. Overgard J. The current and potential role of hyperthermia in radiotherapy. Int J Radiat Oncol Biol Phys 1989; 16: 535-49.
64. Van der Zee J, Wust P. Hyperthermia and radiotherapy. Prog Radio-Oncol VII 2002; 653.